Dupont Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Dupont Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-34,893	Closed	-$244K	–	1691
2020 Q4	$244K	Sell	34,893 -2,605	-7%	-$20.3K	0.01%	1104
2020 Q3	$306K	Buy	+37,498	New	+$233K	0.01%	966
2020 Q1	–	Sell	-67,276	Closed	-$587K	–	1402
2019 Q4	$587K	Buy	+67,276	New	+$364K	0.01%	760
2019 Q3	–	Sell	-64,826	Closed	-$321K	–	1294
2019 Q2	$321K	Buy	+64,826	New	+$344K	0.01%	980

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Dupont Capital Management's JNCE Position: Q1 2021 in Review

Dupont Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 34,893 shares — an estimated $244K sold.

Dupont Capital Management first reported a position in JNCE in Q2 2019 and held it in 4 quarters. The position peaked at $587K in Q4 2019. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

Dupont Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Dupont Capital Management sold 34,893 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $244K.
Dupont Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
Dupont Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $587K in Q4 2019.
124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Dupont Capital Management's 13F filing for Q1 2021, filed 29 Apr 2021.